English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Escitalopram has shown efficacy and tolerability in the prevention of relapse in elderly patients with major depressive disorder (MDD). This  post-hoc  analysis compared time to relapse for  young-old  patients (n = 197) to that for  old-old  patients (n = 108).    Method  Relapse prevention: after 12-weeks open-label treatment, remitters (MADRS ≤12) were randomised to double-blind treatment with escitalopram or placebo and followed over 24-weeks. Patients were outpatients with MDD from 46 European centers aged ≥75 years ( old-old ) or 65-74 years of age ( young-old ), treated with escitalopram 10-20mg/day. Efficacy was assessed using the Montgomery Åsberg Depression Rating Scale (MADRS).    Results  After open-label escitalopram treatment, a similar proportion of  young-old  patients (78%) and  old-old  patients (72%) achieved remission. In the analysis of time to relapse based on the Cox model (proportional hazards regression), with treatment and age group as covariates, the hazard ratio was 4.4 for placebo  versus  escitalopram (χ 2 -test, df = 1, χ 2 = 22.5, p < 0.001), whereas the effect of age was not significant, with a hazard ratio of 1.2 for  old-old  versus  young-old  (χ 2 -test, df = 1, χ 2  = 0.41, p = 0.520). Escitalopram was well tolerated in both age groups with adverse events reported by 53.1% of  young-old  patients and 58.3% of  old-old  patients. There was no significant difference in withdrawal rates due to AEs between age groups (χ 2 -test, χ 2  = 1.669, df = 1, p = 0.196).    Conclusions   Young-old  and  old-old  patients with MDD had comparable rates of remission after open-label escitalopram, and both age groups had much lower rates of relapse on escitalopram than on placebo.

Are old-old patients with major depression more likely to relapse than young-oldpatients during continuation treatment with escitalopram?